The production of Covid-19 vaccine is a major step forward in the fight against this pandemic, but more in-depth studies are still needed on vaccine-related issues. Two new studies showed that Moderna’s Covid-19 vaccine was effective against the variant in California and that its protection lasted for 6 months.
Researchers from Duke University have found that the antibodies produced by Moderna’s vaccine have about 2 times less neutralizing power than the bacteria first detected at Golden State.
The results showed that the vaccine was still very effective, according to the team. Another previous study found the Moderna vaccine was weakened against the British variant, which is currently the dominant strain in the United States, but still offers a high degree of protection.
In another study, scientists from the National Institute of Allergy and Infectious Diseases together with Emory University found that neutralizing antibodies remained high for at least six months.
However, the Center for Disease Control and Prevention (CDC) claims that although Moderna’s vaccine is highly effective, more people have reported a post-injection response compared to the Pfizer-BioNTech vaccine.
For the first study, published in the New England Journal of Medicine, Duke’s team looked at blood samples from 26 people who had received both doses of the Moderna vaccine.
Their serum was then exposed to a California variant, known as B.1.427 / B.1.429. The variant was first identified in May 2020, and barely exists until October.
In a recent study, the University of California, San Francisco looked at 2172 virus samples collected between September 2020 and January 2021 across California. By January, the new variant accounted for more than 50% of all genetically analyzed disease samples. In short, it became the most common strain in California and could account for up to 90% of the state’s infections.
The Moderna vaccine is effective against Covid-19 variants and produces antibodies for at least 6 months but also has some mild side effects.
Laboratory studies conducted by USCF have found that B.1.427 / B.1.429 produces a viral load twice as high as the load activated by the other variants.
The new study found that Moderna vaccine’s protection against the California vaccine was only slightly reduced, with approximately 2 times less neutralizing power. However, for the South African variant, the antibodies produced by the vaccine have 6.7 to 9.7 times lower neutralizing power.
The team says this is good news, because while the California variant is popular in the most populous state of the United States, the South African variants are much less common.
Study author, Dr. David Montefiori, professor and director of the AIDS Vaccine Research and Development Laboratory at Duke Department of Surgery, said: “Fortunately the California variant doesn’t seem to be the problem. with current vaccines. It is important to know that, since this variant is now as popular in the US as the UK variant, both are more contagious ”.
For the second study, published in the New England Journal of Medicine, the team looked at blood samples from 33 healthy participants. All were quantified in the phase 1 trial, and the researchers looked at the degree of binding and neutralization of antibodies more than 200 days after the first dose.
Among all age groups, antibody activity remains high at the 6-month mark. “The antibodies produced by the vaccine persist for 6 months after the second dose,” wrote the authors.
Ongoing studies are monitoring immune responses after 6 months as well as determining the effect of booster doses to prolong the duration and range of action against mutants.
The report echoes what Pfizer-BioNTech reported last week about their Covid-19 vaccine, which works in a similar way to Moderna’s type.
However, while Moderna’s protective abilities have been confirmed, many reports from users have said they experienced more side effects than those who received Pfizer-BioNTech injections.
In a new study, published in JAMA, CDC researchers looked at reports gathered through V-SAFE, using text messages and web surveys to get vaccinated people. If they are experiencing any side effects, write it down.
After the first dose, people who received Moderna injections were more likely to experience side effects. For example, 73.9% of Moderna injecters reported injection site reactions, such as pain or redness, compared with 65.4% of Pfizer injecters.
Additionally, 51.7% of Moderna users reported reactions such as headache, fever, or chills compared with 48% of those who injected Pfizer.
The difference between the two vaccines increases after the second dose. A total of 81.9% of Moderna injecters reported injection site reactions and 74.8% reported other side effects. Similarly, 68.6% of those who received Pfizer received a topical reaction and 64.2% had other symptoms.
It is currently unclear why many people who receive the Moderna injection report side effects. The National Institutes of Health is opening an investigation to see why some people have allergic reactions to Pfizer and Moderna vaccines.
Huong Giang (Source: dailymail)